EUCTR2014-003083-21-FR进行中（未招募）1 期
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (Anti-PDL1 ANTIBODY) COMPARED WITH CISPLATIN OR CARBOPLATIN+PEMETREXED FOR PD-L1-SELECTED CHEMOTHERAPY NAIVE PATIENTSWITH STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 572
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •ECOG performance status of 0 or 1
- •Histologically or cytologically confirmed, Stage IV non-squamous NSCLC
- •No prior treatment for Stage IV non-squamous NSCLC, unless patient had a previously detected sensitizing EGFR mutation or ALK fusion oncogene
- •oPatients with a known sensitizing mutation in the EGFR gene or ALK fusion oncogene must have experienced disease progression or intolerance to treatment any EGFR TKI approved for the treatment of EGFR-mutant NSCLC or any ALK inhibitor approved for the treatment of NSCLC in patients having an ALK fusion oncogene, respectively.
- •Patient with a history of treated asymptomatic CNS metastases
- •Tumor PD-L1 expression as determined by an IHC assay performed by a central laboratory on previously obtained archival tumor tissue or tissue obtained from a biopsy at screening
- •Measurable disease, as defined by RECIST v1.1
- •Adequate hematologic and end-organ function
- •For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception and to continue its use for 90 days after the last dose of MPDL3280A
- •Women who are not postmenopausal (? 12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 280
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 120
排除标准
- •Active or untreated CNS metastases as determined by CT or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
- •Leptomeningeal disease
- •Uncontrolled tumor-related pain
- •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
- •Uncontrolled or symptomatic hypercalcemia
- •Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death
- •History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
- •History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
- •Positive test for HIV
- •Patients with active hepatitis B or hepatitis C
- •Active tuberculosis
- •Severe infections within 4 weeks prior to randomization, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
- •Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to randomization, unstable arrhythmias, or unstable angina
- •Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment
- •Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to randomization
- •Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-PD-1, and anti-PD-L1 therapeutic antibodies
- •Treatment with systemic immunostimulatory agents (including but not limited to interferons, IL-2) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to randomization
- •Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to randomization
研究者
相似试验
进行中（未招募）
1 期
A clinical phase III study that investigates the efficacy of Atezolizumab in combination with carboplatin-paclitaxel with or without bevacizumab compared with carboplatin-paclitaxel-bevacizumabStage IV non-squamous non small cell lung cancerEUCTR2014-003207-30-PTF. Hoffmann-La Roche Ltd1,200
进行中（未招募）
1 期
A clinical phase III study that investigates the efficacy of MPDL3280A in combination with carboplatin-paclitaxel with or without bevacizumab compared with carboplatin-paclitaxel-bevacizumabStage IV non-squamous non small cell lung cancerEUCTR2014-003207-30-FRF. Hoffmann-La Roche Ltd1,200
进行中（未招募）
1 期
Phase 3 study of immunotherapy combined with growth factor inhibitors compared to conventional sunitinib for advanced kidney cancerEUCTR2014-004684-20-PLF. Hoffmann-La Roche Ltd915
进行中（未招募）
不适用
Study to evaluate the safety and efficacy of MPDL3280A (anti-PDL1 antibody) compared to platinum-based chemotherapy in patients with metastatic, non-squamous, PD-L1-selected, non-small cell lung cancer that has not been treated with chemotherapy.EUCTR2014-003083-21-ESF. Hoffmann-La Roche Ltd400
进行中（未招募）
1 期
Safety and efficacy of MPDL3280A (anti-PDL1 antibody) compared to gemcitabine + platinum-based chemotherapy in previously untreated patients with metastatic, squamous, PD-L1-selected, non-small cell lung cancer.Previously untreated Stage IV, Squamous, Non-Small Cell Lung CancerEUCTR2014-003106-33-GRF. Hoffmann-La Roche Ltd400